Drug
Zastaprazan clinical trials
Also written JP-1366.
- studies test it
- 14
- open now
- 7
- in phase 3
- 6
- first study started
- 2019
Keep track of what changes. Save the zastaprazan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 1
- Phase 3
- 6
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 4
Onconic Therapeutics Inc. (10) · Asan Medical Center (1) · Samsung Medical Center (1) · Yonsei University (1) · Incheon St.Mary's Hospital (1)
Often tested with
Tested in the same studies.
JLP-2302 (1) · Clarithromycin (1) · Rabeprazole (1) · Clopidogrel (1) · Aspirin (1) · Atorvastatin (1) · Apixaban (1)
Studies
Open first, then newest update. How each study uses zastaprazan is read from its arms, and is right about nine times in ten.
Testing it · 14
- Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic StrokeNot yet recruitingPhase 3Asan Medical CenterNCT07730840Written as Zastaprazan
- Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive EsophagitisNot yet recruitingPhase 3Onconic Therapeutics Inc.NCT07732075Written as JP-1366 10 mg
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial InfarctionRecruitingPhase 3Samsung Medical CenterNCT07467213Written as Zastaprazan
- Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRventionRecruitingPhase 4Yonsei UniversityNCT07471867Written as Zastaprazan
- Heartburn, Gastroesophageal Reflux DiseaseRecruitingPhase 4Incheon St.Mary's HospitalNCT07268820Written as Zastaprazan
- to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and ApixabanRecruitingPhase 1Onconic Therapeutics Inc.NCT07265466Written as JP-1366 and clopidogrel
- Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic UlcersRecruitingPhase 3Onconic Therapeutics Inc.NCT06439563Written as JP-1366 10 mg
- Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy VolunteersCompletedPhase 1Onconic Therapeutics Inc.NCT07181538Written as JP-1366
- JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive EsophagitisCompletedPhase 3Onconic Therapeutics Inc.NCT05443984Written as JP-1366 20mg
- Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric UlcerCompletedPhase 3Onconic Therapeutics Inc.NCT05448001Written as JP-1366 20mg
- Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy VolunteersCompletedPhase 1Onconic Therapeutics Inc.NCT05712681Written as JP-1366 20mg tablet
- Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult VolunteersCompletedPhase 1Onconic Therapeutics Inc.NCT05814809Written as JP-1366 20mg tablet
- Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux DiseaseCompletedPhase 2Onconic Therapeutics Inc.NCT04282954Written as JP-1366
- Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy VolunteersCompletedPhase 1Onconic Therapeutics Inc.NCT05194046Written as JP-1366 20mg 1capsule
As the comparator · 1 — what is tested is compared with zastaprazan
Codes
What other systems call zastaprazan · ClinicalTrials.gg INT018334
- UNII (FDA) W9S9KZX5MDZASTAPRAZANConfirmed FDA, Wikidata
- Wikidata Q131599122zastaprazanConfirmed FDA, Wikidata
- NCI Thesaurus C184895ZastaprazanOne source FDA
- DrugBank DB21524One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W9S9KZX5MD | ZASTAPRAZAN | Confirmed FDA, Wikidata |
| Wikidata | Q131599122 | zastaprazan | Confirmed FDA, Wikidata |
| NCI Thesaurus | C184895 | Zastaprazan | One source FDA |
| DrugBank | DB21524 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.